Trial
NCT02078960
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Collaborators
—
Condition
Chronic Myeloid Leukemia
Intervention
Omacetaxine mepesuccinate
Why stopped
Inability to accrue additional sites and enroll an adequate number of subjects.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-09